[go: up one dir, main page]

WO2012037232A3 - Compositions, methods and kits for detecting and treating alzheimer's disease - Google Patents

Compositions, methods and kits for detecting and treating alzheimer's disease Download PDF

Info

Publication number
WO2012037232A3
WO2012037232A3 PCT/US2011/051570 US2011051570W WO2012037232A3 WO 2012037232 A3 WO2012037232 A3 WO 2012037232A3 US 2011051570 W US2011051570 W US 2011051570W WO 2012037232 A3 WO2012037232 A3 WO 2012037232A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
compositions
detecting
subject
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/051570
Other languages
French (fr)
Other versions
WO2012037232A2 (en
Inventor
Robert W. Keane
Juan Pablo De Rivero Vaccari
W. Dalton Dietrich
Deborah Carmen Mash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of WO2012037232A2 publication Critical patent/WO2012037232A2/en
Publication of WO2012037232A3 publication Critical patent/WO2012037232A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions, kits and methods for detecting AD in a subject at an early stage include in vitro or in vivo analysis of expression of one or more markers of pre-AD. Screening platforms for identifying a therapeutic agent for preventing or treating AD in humans, and kits for detecting the presence of AD in a subject at an early stage are described herein. Compositions and methods for preventing or delaying onset of AD in a subject include a therapeutically effective amount of an inhibitor of at least one of the following proteins: an RIG-1 signaling pathway member, MDA5, VISA, RIG-1, NLRP12, and an HERV protein for inhibiting death and damage of neurons in the subject having pre-AD and a pharmaceutically acceptable carrier.
PCT/US2011/051570 2010-09-16 2011-09-14 Compositions, methods and kits for detecting and treating alzheimer's disease Ceased WO2012037232A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38343410P 2010-09-16 2010-09-16
US61/383,434 2010-09-16

Publications (2)

Publication Number Publication Date
WO2012037232A2 WO2012037232A2 (en) 2012-03-22
WO2012037232A3 true WO2012037232A3 (en) 2012-07-05

Family

ID=45832218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/051570 Ceased WO2012037232A2 (en) 2010-09-16 2011-09-14 Compositions, methods and kits for detecting and treating alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2012037232A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103578183A (en) * 2012-08-03 2014-02-12 华为技术有限公司 Method, device and electronic device for displaying amount of user account
WO2017185022A1 (en) * 2016-04-21 2017-10-26 University Of Vermont And State Agricultural College Mitochondrial antiviral-signaling (mavs) polypeptides and detection and use thereof
US20220332799A1 (en) * 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
CN112946300A (en) * 2021-03-19 2021-06-11 苏冬梅 Alzheimer disease early detection kit based on Western Blot method and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244890A1 (en) * 2003-11-07 2005-11-03 Davies Huw A Biomarkers for Alzheimer's disease
US20070082347A1 (en) * 2005-06-08 2007-04-12 Myriad Genetics, Incorporated Gene variants and use thereof
US20070160609A1 (en) * 1995-07-14 2007-07-12 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160609A1 (en) * 1995-07-14 2007-07-12 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US20050244890A1 (en) * 2003-11-07 2005-11-03 Davies Huw A Biomarkers for Alzheimer's disease
US20070082347A1 (en) * 2005-06-08 2007-04-12 Myriad Genetics, Incorporated Gene variants and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAGELE ET AL.: "Double-stranded RNA activates type 1 interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1", NEPHROL. DIAL. TRANSPLANT., vol. 24, 16 July 2009 (2009-07-16), pages 3312 - 3318 *

Also Published As

Publication number Publication date
WO2012037232A2 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2007112052A3 (en) Formulations and methods for vascular permeability-related diseases or conditions
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
WO2009043159A8 (en) Neural tumor stem cells and methods of use thereof
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP1723251A4 (en) IN VITRO TESTING SYSTEM FOR PREDICTING THE TOLERABILITY OF THERAPEUTIC AGENTS IN PATIENTS
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
BRPI0918194A2 (en) '' compound, pharmaceutical composition, use of a compound, method for treating an individual suffering from a pathological condition or disease and combination product
WO2010042489A3 (en) Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
EA201101450A1 (en) THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRABLE CELL PROLIFERATION
WO2008083160A3 (en) Methods and compositions for therapeutic treatment
TN2013000073A1 (en) Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease
WO2011041452A3 (en) Mouse model for identifying compounds for the treatment of oxidative stress
IL290418A (en) Immune checkpoint inhibitor, therapeutic agent for immune checkpoint-related disease, immunosuppressant, anti-fibronectin antibody or derivative thereof, fibronectin analog, kit for detecting fibronectin or partial protein thereof, and method for detecting fibronectin or partial protein thereof
WO2012037232A3 (en) Compositions, methods and kits for detecting and treating alzheimer's disease
Bang et al. Preconditioning stimulus of proteasome inhibitor enhances aggresome formation and autophagy in differentiated SH-SY5Y cells
EP2164990A4 (en) COMPOSITIONS, KITS AND METHODS FOR CANCER IDENTIFICATION, EVALUATION, PREVENTION AND THERAPY
WO2009043858A3 (en) Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease
FR2903312B1 (en) USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT
WO2011009193A8 (en) Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies
PL1889920T3 (en) In vitro cancer therapy compound identification method
TNSN07038A1 (en) Methods for improving bioavailability of a renin inhibitor
FR3068045B1 (en) RECONSTITUTED SENSITIVE SKIN MODELS
WO2007083287A3 (en) Test method for assessing irritation of skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11825859

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11825859

Country of ref document: EP

Kind code of ref document: A2